KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $136.3 million.

  • Halozyme Therapeutics' Operating Expenses rose 745.23% to $136.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.5 million, marking a year-over-year increase of 746.43%. This contributed to the annual value of $463.8 million for FY2024, which is 566.02% down from last year.
  • Halozyme Therapeutics' Operating Expenses amounted to $136.3 million in Q3 2025, which was up 745.23% from $123.3 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Operating Expenses peaked at $136.3 million during Q3 2025, and registered a low of $38.3 million during Q1 2021.
  • In the last 5 years, Halozyme Therapeutics' Operating Expenses had a median value of $118.3 million in 2022 and averaged $99.9 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Operating Expenses surged by 21230.49% in 2022, and later tumbled by 984.52% in 2024.
  • Halozyme Therapeutics' Operating Expenses (Quarter) stood at $45.5 million in 2021, then soared by 135.3% to $107.0 million in 2022, then increased by 20.58% to $129.0 million in 2023, then decreased by 5.04% to $122.5 million in 2024, then rose by 11.29% to $136.3 million in 2025.
  • Its Operating Expenses stands at $136.3 million for Q3 2025, versus $123.3 million for Q2 2025 and $123.3 million for Q1 2025.